...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Academic radiology >MR-guided high-intensity focused ultrasound treatment for symptomatic uterine leiomyomata: long-term outcomes.
【24h】

MR-guided high-intensity focused ultrasound treatment for symptomatic uterine leiomyomata: long-term outcomes.

机译：MR引导的高强度聚焦超声治疗有症状的子宫平滑肌瘤：长期结果。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

RATIONALE AND OBJECTIVES: To evaluate the long-term clinical outcomes of magnetic resonance--guided high-intensity focused ultrasound (MR-g HIFU) treatments for symptomatic uterine leiomyomata. MATERIALS AND METHODS: Patients were recruited for a prospective study for MR-g HIFU treatments of symptomatic leiomyomata, with up to 3-year follow-up. The study was approved by the institutional review board and was Health Insurance Portability and Accountability Act--compliant. Clinical assessments were obtained at 3 months, 6 months, and 1, 2, and 3 years after MR-g HIFU, as well as uterine fibroid symptom severity scores (SSS) and health-related quality of life questionnaires (UFS-QOL). MR imaging was performed at each follow-up to assess the efficacy of the treatment at 6 months, 1 year, 2 years, and 3 years. RESULTS: Fifty-one leiomyomata in 40 patients were treated. All patients were treated within the US Food and Drug Administration guidelines with leiomyomata localized on MR and treated with sonication. The mean baseline volume of treated leiomyomata was 336.9 cm(3). The mean improvement scores for transformed SSS was 47.8 (P < .001) and for tUFS-QOL was 39.8 (P < .001) at 3 years. The mean volume decrease in treated leiomyomata was 32.0% (P < .001), and, in the uterus, the volume decrease was 27.7% (P < .001) at 3 years. There were no long-term complications. CONCLUSIONS: Long-term follow-up data from MR-g HIFU treatments show sustained symptomatic relief among enrolled patients. Although the results are preliminary, MR-g HIFU for the treatment of uterine leiomyomata may result in acceptable long-term outcomes at 3 years.
机译：理由和目的：评价磁共振引导的高强度聚焦超声（MR-g HIFU）治疗有症状子宫平滑肌瘤的长期临床疗效。材料与方法：招募患者进行前瞻性研究，以对症性平滑肌瘤进行MR-g HIFU治疗，并随访3年。该研究得到机构审查委员会的批准，并且符合《健康保险流通与责任法案》的要求。在MR-g HIFU后3个月，6个月，1、2和3年获得临床评估，以及子宫肌瘤症状严重程度评分（SSS）和健康相关的生活质量问卷（UFS-QOL）。每次随访均进行MR成像，以评估6个月，1年，2年和3年时的治疗效果。结果：治疗40例患者中的51例平滑肌瘤。所有患者均在美国食品药品监督管理局的指导下接受了平滑肌瘤的MR定位并超声处理。治疗的平滑肌瘤的平均基线体积为336.9 cm（3）。在3年时，转化的SSS的平均改善得分为47.8（P <.001），而tUFS-QOL的平均改善得分为39.8（P <.001）。治疗的平滑肌瘤的平均体积减少为32.0％（P <.001），而在子宫中，3年时的体积减少为27.7％（P <.001）。没有长期并发症。结论：MR-g HIFU治疗的长期随访数据显示，入组患者的症状持续缓解。尽管结果是初步的，但是MR-g HIFU治疗子宫平滑肌瘤可能会在3年时带来可接受的长期结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号